KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Long-Term Deferred Tax: 2012-2013

  • Arbutus Biopharma's Long-Term Deferred Tax rose 3.59% to $16.3 million in Q4 2013 from the same period last year, while for Dec 2013 it was $16.3 million, marking a year-over-year increase of 3.59%. This contributed to the annual value of $16.3 million for FY2013, which is 3.59% up from last year.
  • Per Arbutus Biopharma's latest filing, its Long-Term Deferred Tax stood at $16.3 million for Q4 2013, which was up 3.59% from $15.7 million recorded in Q4 2012.
  • Over the past 5 years, Arbutus Biopharma's Long-Term Deferred Tax peaked at $16.3 million during Q4 2013, and registered a low of $15.7 million during Q4 2012.
  • For the 2-year period, Arbutus Biopharma's Long-Term Deferred Tax averaged around $16.0 million, with its median value being $16.0 million (2012).
  • Data for Arbutus Biopharma's Long-Term Deferred Tax shows a peak YoY rose of 3.59% (in 2013) over the last 5 years.
  • Arbutus Biopharma's Long-Term Deferred Tax (Quarterly) stood at $15.7 million in 2012, then increased by 3.59% to $16.3 million in 2013.